TrialSite News: “Errant Gene Therapeutics’ Gene Therapy Vector Shows Promise for Sickle Cell Disease and Thalassemia Patients”

May 23, 2020 | News

The abstract submitted to the European Hematology Association by Dr. Simona Raso for a new analysis of the safety and efficacy of Errant Gene Therapeutics’ vector, technically “human globin TNS9.3.55,” shows promising results and potentially offers newfound hope for the 1.8 million worldwide who suffer from the rare diseases Sickle Cell Anemia and Thalassemia. The study analyzes the use of the EGT vector on three patients at Memorial Sloan Kettering from 2012 to 2015, with a five to seven-year follow-up.

Read More at TrialSite News

View PDF

Contact us

Call Us

+1 (312) 441-1800

Our Locations

San Rocco Therapeutics
308 E. Emily St.
Tampa, FL 33603


Get in touch